ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma.
about
The Role of ATRX in the Alternative Lengthening of Telomeres (ALT) PhenotypeEpigenetic Regulation of Telomere Maintenance for Therapeutic Interventions in Gliomas.Single vs. combination immunotherapeutic strategies for glioma.ATRX mutations and glioblastoma: Impaired DNA damage repair, alternative lengthening of telomeres, and genetic instability.Recent advances and future of immunotherapy for glioblastoma.Mutated Chromatin Regulatory Factors as Tumor Drivers in CancerCharacterizing and targeting PDGFRA alterations in pediatric high-grade glioma.The Effect of Molecular Diagnostics on the Treatment of Glioma.Further understanding of the pathology of glioma: implications for the clinic.Key rates for the grades and transformation ability of glioma: model simulations and clinical cases.Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors.Cancer Cells with Alternative Lengthening of Telomeres Do Not Display a General Hypersensitivity to ATR Inhibition.The Role of ATRX in Glioma Biology.Diagnosis and treatment of ALT tumors: is Trabectedin a new therapeutic option?Alpha Thalassemia/Mental Retardation Syndrome X-Linked, the Alternative Lengthening of Telomere Phenotype, and Gliomagenesis: Current Understandings and Future Potential.Addition of Amide Proton Transfer Imaging to FDG-PET/CT Improves Diagnostic Accuracy in Glioma Grading: A Preliminary Study Using the Continuous Net Reclassification Analysis.New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.Frequent alternative lengthening of telomeres and ATRX loss in adult NF1-associated diffuse and high-grade astrocytomas.Characterizing genomic differences of human cancer stratified by the TP53 mutation status.Current state and future prospects of immunotherapy for glioma.Survival and Proliferation of Neural Progenitor-Derived Glioblastomas Under Hypoxic Stress is Controlled by a CXCL12/CXCR4 Autocrine-Positive Feedback Mechanism.Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival.Atrx inactivation drives disease-defining phenotypes in glioma cells of origin through global epigenomic remodeling.Spontaneous development of intratumoral heterogeneity in a transposon-induced mouse model of glioma.Aberrant ATRX protein expression is associated with poor overall survival in NF1-MPNST.Mutant ATRX: uncovering a new therapeutic target for glioma.Molecular Ablation of Tumor Blood Vessels Inhibits Therapeutic Effects of Radiation and Bevacizumab.Molecular Markers of Therapy-Resistant Glioblastoma and Potential Strategy to Combat Resistance.Potential Strategies Overcoming the Temozolomide Resistance for GlioblastomaA potential common role of the Jumonji C domain-containing 1A histone demethylase and chromatin remodeler ATRX in promoting colon cancerATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner
P2860
Q28071562-C89E63C0-BB88-43F2-A34D-2E778FE4C7E7Q33737472-7410D4AD-F960-47C5-AEA2-3CB695280423Q33746041-26BAE75D-7A54-457A-BBBE-70D2093EAAAAQ37008597-02C2CA79-4D72-4D3F-93D8-5455554128E1Q37239071-CA205224-DD37-4293-88BC-41EC86B7933EQ37592666-DCBFF39B-23DA-41E5-AD0C-BD880E56EF24Q37662300-1819071E-E260-4B37-BAD7-79C911AD61C6Q38743781-ABF61EAC-A344-4D99-97A8-66FB1C5D29A3Q38844945-E4793079-1797-4543-8018-66C75F917CA1Q39268920-AEAC935E-93DE-4C0C-9668-9E4487977C66Q40260723-A0B9078E-7B30-4685-BD12-71DA8D0295FFQ41439061-9FED91EB-C0C5-45F7-A3DF-1D28260A6553Q42369808-0C964C0B-2074-480F-826E-D880F554C092Q47095909-F5CD1F87-C294-41C0-A385-9B9F870CA8D1Q47552952-93B20ADE-AB92-424F-9B8B-6639CF28FB91Q47883026-F655CF19-0666-488F-97CD-78FE5261AEECQ47934716-8D15942A-C4EB-4796-9AB3-EF2E89A703C3Q48468812-2E26F8E6-A6E4-45A6-B005-70C7537FB84DQ50057990-57BBF07E-9750-4B30-B8B0-99DF611735C6Q50109459-6B7ED312-1FFC-4121-B013-97D3FB13B92AQ50491825-177A9A2C-FE6E-4925-86C7-1DBC1B1AA6F8Q51468560-CF4DD9ED-4DD5-4C17-9C0C-996E6466E854Q52657331-8D4E3C31-47E0-4693-B7F2-EAE47F230937Q52724352-30B75214-FE8F-4658-912F-C6D7A7640D13Q55383206-E06F51A5-15C3-4032-8B5B-E6DA29933FE0Q55456861-A3F82811-DFE8-4EB9-96B3-285667402847Q55457297-AD414768-6E32-4E88-9593-040F57C4D14CQ55663256-3C8D5890-AF60-4FD1-9DBC-EB1C5B0463EAQ57153312-63C06E5D-9A17-4863-B64E-B3CE704673A9Q58572320-ECBF3A2E-4FA7-4FEB-86A1-98CCD718E0CBQ58727164-706E2B5C-0B63-4BF9-AF1D-F998E00B1F94
P2860
ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
ATRX loss promotes tumor growt ...... joining DNA repair in glioma.
@en
ATRX loss promotes tumor growt ...... joining DNA repair in glioma.
@nl
type
label
ATRX loss promotes tumor growt ...... joining DNA repair in glioma.
@en
ATRX loss promotes tumor growt ...... joining DNA repair in glioma.
@nl
prefLabel
ATRX loss promotes tumor growt ...... joining DNA repair in glioma.
@en
ATRX loss promotes tumor growt ...... joining DNA repair in glioma.
@nl
P2093
P2860
P50
P1476
ATRX loss promotes tumor growt ...... joining DNA repair in glioma.
@en
P2093
Alan Mackay
Alan Meeker
Carl Koschmann
Daniel Thomas
David Ferguson
Felipe J Nunez
Flor Mendez
Henry Appelman
Jacqueline A Brosnan-Cashman
Janet Fazal-Salom
P2860
P304
P356
10.1126/SCITRANSLMED.AAC8228
P407
P577
2016-03-01T00:00:00Z